Table 4.

Impact of Active as Compared with Treatment >30 days prior to Survey Administration on Utilities by Stage at Diagnosis and Treatment

Demographic	% Patients with Utility Scores	Mean (SD) EQ-5D Utility N=2396	Median (IQR) EQ-5D Utility N=2396	Mean (SD) SF-6D Utility N=2344	Median (IQR) SF-6D Utility N=2344
All	100	0.78 (0.18)	0.82 (0.15)	0.68 (0.14)	0.66 (0.20)
Active Treatment <=30 Days	45%	0.77 (0.14)	0.82 (0.15)	0.66 (0.13)	0.65 (0.16)
Active Treatment >30 Days	55%	0.79 (0.18)	0.82 (0.15)	0.70 (0.14)	0.68 (0.20)
p-value*			0.0209*		0.0001
Stage I Treatment
Active <=30 Days	21%	0.81 (0.14)	0.82 (0.10)	0.68 (0.12)	0.66 (0.20)
Active >30 Days	79%	0.81 (0.17)	0.83 (0.23)	0.72 (0.15)	0.72 (0.25)
p-value*			n.s.		0.0033**
Stage II Treatment
Active <=30 Days	43%	0.75 (0.19)	0.78 (0.25)	0.67 (0.14)	0.65 (0.20)
Active >30 Days	57%	0.78 (0.16)	0.82 (0.12)	0.69 (0.13)	0.66 (0.20)
p-value*			n.s.		n.s.
Stage III Treatment
Active <=30 Days	59%	0.78 (0.17)	0.82 (0.15)	0.66 (0.13)	0.65 (0.16)
Active >30 Days	41%	0.76 (0.18)	0.82 (0.14)	0.69 (0.14)	0.66 (0.19)
p-value*			n.s.		n.s.
Stage IV Treatment
Active <=30 Days	62%	0.77 (0.19)	0.82 (0.15)	0.66 (0.12)	0.66 (0.16)
Active >30 Days	38%	0.76 (0.20)	0.80 (0.17)	0.67 (0.14)	0.66 (0.17)
p-value*			n.s.		n.s.

^*p-value is significant due to differences in rank sum when using the Mann-Whitney test,(13) non-significant after Bonferroni adjustment

^**non-significant after Bonferroni adjustment